Brown & Brown (BRO)
NYSEFinancialsInsurance - BrokersSnapshot 2026-10-29
NYSEFinancialsInsurance - BrokersSnapshot 2026-10-29
Research Workspace
Put BRO beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Financials is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Increase Adjusted Diluted Net Income Per Share: Comparison needs review.
View ThesisRevenue growth is accelerating — up about 26% over the past year.
View GrowthRanks in the weakest quality tier of its industry — roughly the bottom 32%, softest on share dilution.
View QualityMiddle-of-the-pack management execution.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskBRO’s core case rests on organic revenue growth and acquisition integration. Revenue growth slowed from 35.4% to 7.4%, with the latest quarter missing earnings. The latest non-GAAP result was $1.07 per share, below $1.08 consensus. The price reflects less growth than our forecast. BRO trades at 15× P/E versus 12× for peers, near its 16× history. That premium contrasts with expectations that look modest versus our view. Reported profits are not well backed by cash. Our model puts the next-quarter miss probability near 25%. Peer multiples imply a price about 5% below where it trades. The thesis is on watch, and this read is provisional.
Trailing returns as of 2026-10-30. BRO is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 22 analysts currently covering BRO (as of Oct 2026).
Based on 3 Wall Street analysts offering 12-month price targets for BRO in the last 4 months.
Continue this research
Compare BRO with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| BRO Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 13 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Insurance Brokers — fair value, gap to price, and forward P/E.
Compare the value case
Put BRO next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Integrate Accession and expand through acquisitions
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $69.76
The last 12 months of price, then the range of analyst 12-month targets from today’s $69.76.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Synergy target supports acquisition integration, while projected 2027 retail organic growth remains modest.

Advances: Increase Organic Revenue with Contingents
Partnership enhances organic revenue growth potential.
Advances: Increase Organic Revenue with Contingents
Bullish rating supports growth in organic revenue.

Advances: Increase Organic Revenue with Contingents
Strong Q2 results support organic revenue growth objective.
Advances: Increase Organic Revenue with Contingents
AI partnerships enhance growth potential and organic revenue.
Threatens: Increase Organic Revenue with Contingents
Missed revenue estimates indicate potential growth issues.
Threatens: Increase Organic Revenue with Contingents
Downgrade indicates potential growth concerns impacting revenue.

Threatens: Increase Organic Revenue with Contingents
Softness in organic growth impacts revenue objectives.